We live in an age of amazing technological change with the potential to improve the human condition. This period is distinguished from other historical eras of discovery, by the rapidity with which this is occurring.
The new genome mapping techniques and the Watson artificial intelligence technology are excellent examples, facilitating the scanning of thousands of scientific data, articles, and other reports and producing in mere hours or days computer-generated answers to questions that otherwise would take months or years. This holds true for advances in science in general and for our purposes, medical practice, and research in particular. There are also profound implications for government policy and funding, and insurance costs. However, these advances inevitably raise concerns over the potential for harm. Societies have frequently dealt post facto with practical, legal, and ethical questions posed by undesirable side effects or outcomes, both anticipated and unanticipated. Many legal and ethical advances have followed rather than preceded these technological changes, and as we struggle to address these issues, the rapid discoveries are already bringing further unforeseen challenges. The original Baltimore/Asilomar rules on genetic manipulation were prompted by molecular genetic discoveries and have been more recently reinforced to meet the challenges posed by the new CRISPR technology. At an earlier time, it was the ethical lapses of the Tuskegee study, which prompted the promulgation of the Common Rule for ethical oversight in the United States. 1, 2 The vast array of patient information, biological and data-based, present in storage banks in hospitals, clinics, pharmaceutical firms, and governmental repositories, raise new ethical issues. The term "big-data" usually describes information from multiple repositories and institutions, some well-established, but some also from unconventional sources such as social media. [1] [2] [3] [4] These big data banks and the technology available to scan enormous quantities of information with blinding rapidity pose serious challenges to our ethical landscape, 2 both at the level of institutional review boards (IRBs) reviewing local research proposals and on a more global level, when governing ethical practice in multi-national, multi-institutional investigation.
Multiple sclerosis, perhaps more than many other diseases, necessitates using "big data" from both public and restricted sources. Genetic, immune, epidemiological, and environmental factors, all of which play a role in influencing etiology, progression, and response to therapy, are inextricably intertwined, and the data informing each of them may exist in completely separate types of databases. In the absence of global guidelines and regulations, these are presently all assessed for ethical compliance by local IRBs, with vastly differing rules and outcomes.
The article by Bereza in this issue is thus timely and valuable. The author, an ethicist, discusses the issues facing local IRBs overseeing the use of database material for outcome research; among these are the different types of databases, anonymization, secondary use of data, and consent. He emphasizes the variation in IRB rules when assessing local research proposals on clinical research, even when the researchers use "big data" bank material derived elsewhere.
He highlights the inherent tension facing IRBs and researchers in weighing up the potential benefits to society against the needs to protect the patients. The standardization of terminology, definition of databases, and subsequent IRB decisions are not always consistent and may vary widely from one institution to another. This creates confusion among scientists across the larger national and international communities and may potentially exclude research participation by some centers. The confusion of definitions may impact ethical approval in three major, but inter-related areas: databanks, anonymization, and consent.
Data may be derived from a primary study to answer a specific question, or these data may be used secondarily for a different study. Data from a duly constituted databank may also be used for a project entirely different from its original purpose. Each type may have different ethical and legal restrictions and levels of rigor, but these are not always clear to researchers, or indeed to IRBs. How and from where these data sets are derived (clinical trials, patient records, and public records) may govern rules for privacy and consent, and for who can use the data and for what purpose.
Researchers should be aware of the subtleties of different levels of anonymization to ensure privacy, and the different ethical requirements for each. Unfortunately, these are not harmonized across the research community, with some boards and researchers holding that only complete anonymization can ensure privacy. This requirement however can lead to constraints on research, and in some rare diseases may be impossible to achieve.
The alternative to complete anonymization may lie in a more rigorous consent process. Broad or blanket consent for any research use may be rejected by some ethicists as being uninformed consent, but many ethicists are pointing to pathways to consent that are tailored to specific data sets and questions. 4 In these situations, the size and nature of the database may mitigate the risk of loss of confidentiality and thus lower the need for specific consent. Bereza does not raise the point, but there is an unresolved ethical concern about who holds the basic personal information that is to be anonymized. For instance, a pharmaceutical firm may hold all the detailed personal details on each patient in a large clinical trial, even though the information released for publication is anonymized.
Finally, the author calls for harmonization of the rules and terminology by regional, national, and international bodies, as has been done by others. 5 In resolving ethical and legal issues post facto, other pressures are being felt. A more activist patient community, the rise of open science, new information technology, and the desire to tilt the balance in favor of scientific progress, are also strong motivators for a re-examination of the need for changes in some of the current consent paradigms. Patients living with chronic disease are often highly sophisticated and informed, and as participants in the research may provide useful insights into these issues. The author ends with an interesting comment that the big data era may end the "paternalism of IRBs in favour of a more valorising approach to research."
The article offers useful advice for efficiency and harmonization of individual or linked IRBs, in the oversight of big data projects. However, this article begs the question of the scene beyond the IRBs. In the United States, and in other countries where the Common Rule or equivalent applies to federally granted research, much research still takes place outside of classical IRB oversight and is carried out by the media, agencies, industry, and businesses which may not be bound by the Rule. 1,2,6 A similar situation exists in Canada in the application of the Tri-Council Policy Statement on human research ethics.
Ethical oversight is also rendered more complex when various forms of database are mingled. The argument that data existing in the public domain are not bound by common rules of privacy and consent can lead to enormous lapses in ethical behavior. Social media platforms hold huge amounts of data on users, including very personal information, and can release "studies" and reports unrestricted by any of the traditional ethical oversight. Merging of public and private databases has also increased the possibility that subjects may more easily be identified. 2 In fact, there is considerable discussion in the literature and within legislative and administrative bodies to search for ways of going beyond the current laws on privacy, to allow for certain exemptions from the "consent or anonymise" model of medical research to maximize scientific progress. 4 The European Union 4, 7 and other organisations 1 are starting such initiatives, but the problems are many and will require widespread agreement and fine balancing of the personal risks and the public good 1, 4, 8 including possible changes to the Common Rule. 1 These arguments have been gathered under the term of "big data exceptionalism." However, others have championed the need to retain informed consent to satisfy the pivotal principle of patient autonomy. 6, 7 A case is even being made for privacy protection of algorithmically constructed big data-derived groups, as opposed to individuals. 9 In addition, a central question still persists-who "owns" the patient/participant's data and specimens? 6 Is there a societal duty to make this information available to all? Some ethicists have argued that individuals have an ethical obligation to participate in research. What are the ethical implications of a company profiting from the use of someone's data? Finally, in addition to the ethical principles of privacy and informed consent, there are also implications for the principle of justice, especially in the field of public policy. 3 Will the access to big data only be available to those individuals and populations able to afford them?
Security of the databanks must be ensured. Data stored in the cloud or elsewhere are always at risk, and as reported by the Ponemon Institute, security breaches and threats by malware have risen steadily. 10 Security breaches in the context of big data could be disastrous.
Society faces a period of tremendous introspection and debate dealing with these ethical and legal issues; physicians, scientists, and patients will be at the forefront of this discussion. We must develop coherent approaches to anticipating rapid advances. The diverse nature and uncertain etiology of MS necessitate that those of us living with or treating and researching the causes and management of multiple sclerosis will be an important part of this journey. We owe our patients and their families, present and future our unique contributions to the debate.
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